机构：[1]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beiijing, China重点科室诊疗科室神经外科神经外科首都医科大学附属天坛医院[2]Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beiijing, China研究所北京市神经外科研究所首都医科大学附属天坛医院[3]Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China[4]Department of Neurosurgery, Zhujiang Hospital, Southern Medical University, Guangzhou, China[5]Department of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou, China神经外科普外科苏州大学附属第二医院[6]Center of Brain Tumor, Beijing Institute for Brain Disorders, Beiijing, China[7]China National Clinical Research Center for Neurological Diseases, Beiijing, China[8]Chinese Glioma Genome Atlas Network (CGGA), Beiijing, China
Long noncoding RNAs (lncRNAs) have recently emerged as new potentially promising therapeutic targets in many cancers. However, their prognostic value and biological functions associated with glioma remain to be elucidated. Here, High-throughput RNAseq was performed to detect the expression profiles of lncRNAs in 325 human glioma tissues. It was shown that a novel lncRNA HOXA-AS3 was one of the most significantly upregulated lncRNAs in glioma tissues. Quantitative PCR further verified the increased expression of HOXA-AS3 in patient samples and glioma cell lines. Uni and Multivariate Cox regression analysis revealed that HOXA-AS3 was an independent prognostic factor in glioma patients. Gene set enrichment analysis indicated that the gene sets correlated with HOXA-AS3 expression were involved in cell cycle progression and E2F targets. Functionally, HOXA-AS3 silencing resulted in proliferation arrest by altering cell cycle progression and promoting cell apoptosis, and impaired cell migration in glioma cells. Furthermore, the growth-inhibiting effect of HOXA-AS3 knockdown was also demonstrated in Xenograft mouse model. Our results highlight the important role of HOXA-AS3 in glioma progression, and indicate that HOXA-AS3 may be served as a valuable prognostic biomarker for glioma.
基金：
This work was supported by The National Key Research and Development Plan (No. 2016YFC0902500); Beijing Science and Technology Plan (No. Z131100006113018, Z141100000214009); Capital Medical Development Research Fund (2016-1-1072); China Postdoctoral Science Foundation (2016M601068); National Natural Science Foundation of China (81672479, 81301112, 81402052, 81502495, 81502606) and Beijing Neurosurgical Institute Youth Innovation Fund (2014004).
第一作者机构：[1]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beiijing, China[2]Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beiijing, China[8]Chinese Glioma Genome Atlas Network (CGGA), Beiijing, China
通讯作者：
通讯机构：[1]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beiijing, China[2]Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beiijing, China[6]Center of Brain Tumor, Beijing Institute for Brain Disorders, Beiijing, China[7]China National Clinical Research Center for Neurological Diseases, Beiijing, China[8]Chinese Glioma Genome Atlas Network (CGGA), Beiijing, China
推荐引用方式(GB/T 7714)：
Fan Wu,Chuanbao Zhang,Jinquan Cai,et al.Upregulation of long noncoding RNA HOXA-AS3 promotes tumor progression and predicts poor prognosis in glioma[J].ONCOTARGET.2017,8(32):53110-53123.doi:10.18632/oncotarget.18162.
APA：
Fan Wu,Chuanbao Zhang,Jinquan Cai,Fan Yang,Tingyu Liang...&Tao Jiang.(2017).Upregulation of long noncoding RNA HOXA-AS3 promotes tumor progression and predicts poor prognosis in glioma.ONCOTARGET,8,(32)
MLA：
Fan Wu,et al."Upregulation of long noncoding RNA HOXA-AS3 promotes tumor progression and predicts poor prognosis in glioma".ONCOTARGET 8..32(2017):53110-53123
医学